Urologist @istitutotumori via @HumanitasMilano @MDAndersonNews @NKI_nl Member @EAU_YAUrotheli Member @IBCG_BladderCA
Milano
Joined February 2012
- Tweets722
- Following583
- Followers543
- Likes1.8K
Pinned Tweet
❓️Can we avoid ReTURBT in selected patients with T1 NMIBC? ✅️ According to our study YES!
👥️A response-based approach can spare up to 71% of ReTURBT reducing overtreatment
Full paper➡️euoncology.europeanurology.c…
@EurUrolOncol @urotoday @Uroweb @oncodaily @IBCG_BladderCA
Roberto Contieri retweeted
🚨 Just published in @CHematology
We confirms the benefit of perioperative strategies in #MIBC.
Huge thanks to all co-authors, especially @vmollica7 for the brilliant idea! 👏
@shilpaonc @drenriquegrande @giannatempopatr @OncoAlert @OncoDailyGU
Roberto Contieri retweeted
IBCG2026 Celebrates 20 Years of Advancing Bladder Cancer Care - Roberto Contieri
@RobertoContieri
oncodaily.com/voices/roberto…
🤖 Made with AI
Roberto Contieri retweeted
🩺 UROTHELIAL CANCER UPDATE 2026 🔬 Meets the Guidelines, Challenges the Decisions. Join international experts for a turning point in urothelial cancer management!
🗓️ 18/09 @unito @cittasalute_to @UroMolinette
👨🏫 Chairs: Prof. @paolo_gontero & Prof F Soria
symposiacongressi.com/en/uro…
Roberto Contieri retweeted
Three landmark studies. One network meta-analysis. Which perioperative strategy currently shows the strongest signal for improving survival in muscle-invasive bladder cancer? This analysis compares today's leading approaches and explores what the evidence can—and cannot—tell us.
Article👉 buff.ly/sUECNO9
Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials
This network meta-analysis evaluated perioperative treatment strategies for muscle-invasive #BladderCancer using data from three randomised trials. Compared with gemcitabine–cisplatin, both enfortumab vedotin–pembrolizumab and gemcitabine–cisplatin plus durvalumab📈 improved overall survival, event-free survival, and pathological complete response, with enfortumab vedotin–pembrolizumab ranking highest across outcomes.
Although based on indirect comparisons within a sparse network, these findings help contextualise emerging perioperative treatment options and inform clinical decision-making.
@albisinnidoc
@andreamari08
@FraClaps
@RobertoContieri
@agallioli
@DavDandrea
@E_Laukhtina
@wojciechpiotrk1
@elijeandin
@Luca_Afferi
@f_delgiudice
@UroMoschini
@LAUrology_NL
@Anto_cigliola
@CMercinelli
@MatteoSantoniMD
@BenjaminPradere
@AndreaNecchi
Pinging faculty
@DrChoueiri
@tompowles1
@apolo_andrea
@neerajaiims
@montypal
@Silke_Gillessen
@AOmlin
@brian_rini
@PGrivasMDPhD
@TiansterZhang
@AlbigesL
@cdanicas
@amerseburger
@sonpavde
@DrDanielHeng
@declangmurphy
@seanmmcbride
@HHammersMD
@shilpaonc
@DrRanaMcKay
@scserendipity1
@DrYukselUrun
@scocmem
@ravikanesvaran
@AmandaNizamMD
@drenriquegrande
@BraunMDPhD
@EfstathiouEleni
@nataliagandur
@crisbergerot
Roberto Contieri retweeted
Results of #BOND3 @TheLancetOncol
👉112 pts c BCG UR CIS
👉75% CR
👉46% response at 12mo
👉Favorable AE profile
Compelling data to support use in #BCGURCIS
@MarkTysonMD #EdUchio @garysteinbergmd @tbivala1 #NealShore @JamesBurke34034 @cgoncology
authors.elsevier.com/c/1nVzi…
Roberto Contieri retweeted
Congratulations to @LauraBukavinaMD @jaymsiva @drjkaouk and @ClevelandClinic team on largest external validation of the IBCG IR NMIBC substratification model
📊 2822 patients | 20 years | 3-year recurrence by subgroup:
🟢 IR-low: 12%
🟡 IR-intermediate: 38%
🔴 IR-high: 77%
Progression followed the same stepwise pattern. Fine-Gray competing-risk models confirmed significance (p<0.001) - separation held on 12-month landmark analysis, ruling out early-event bias.
Yet more evidence that trials enrolling IR NMIBC should stratify by IBCG subgroup at enrollment to be clinically meaningful.
Conflating patients with 12% and 77% recurrence risk in the same trial arm is a fundamental problem.
Full text:
authors.elsevier.com/sd/arti… @IBCG_BladderCA
Roberto Contieri retweeted
A multi-center study examines maintenance schedules for intermediate-risk #NMIBC. @RobertoContieri @IstTumori joins @UroDocAsh @UTMDAnderson to discuss the results which include two-year recurrence-free survival of 55% with no maintenance versus 78% with any maintenance. Classification and regression tree analysis identified optimal cutoff at more than six monthly instillations. #WatchNow on UroToday > bit.ly/3OEHP5m
Roberto Contieri retweeted
1) Approval based on marginal improvements in efficacy (without improvement to CSS/OS)
2) Toxicity that isn't G5 (death) doesn't seem to impact approval. 10-15% serious autoimmune AEs in NMIBC is deemed ok
3) little weight given to efficacy vs toxicity balance of a drug
This Post is from an account that no longer exists. Learn more
Excellent lecture by @SScagliarini_ on the growing importance of patient-reported outcomes in oligometastatic RCC. A crucial reminder that beyond oncologic endpoints, understanding the patient perspective is essential to truly optimize treatment strategies.
@Synergy_Uro
@Uroweb – at Naples, Campania
Great pleasure having Prof. Axel Bex at @Synergy_Uro discussing the evolving landscape of locally advanced RCC. Excellent insights and stimulating discussion on current challenges and future directions in kidney cancer care. @eau_yuo
@EAUYAU_RenalCa
@UrowebESU
@EAU_Uroonco – at Naples, Campania
Roberto Contieri retweeted
The definitive #SYNERGY26 programme is out
📆 28–29 May | 📍 Naples
Locally-advanced & Oigometastatic GU cancers Edition.
Program: bit.ly/4w05Zbf
As every year, a packed room for the AUA-IBCG Forum, taking place right now in Salon H.
Great discussions and energy around the future of bladder cancer care and research.
#AUA2026 #BladderCancer @IBCG_BladderCA @UroDocAsh – at Washington, DC
Roberto Contieri retweeted
Synergy 2026: A Global Exchange on Prostate, Kidney, and Bladder Cancer - Roberto Contieri (@RobertoContieri)
oncodaily.com/voices/roberto…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedX
Roberto Contieri retweeted
SYNERGY 2026
🗓️ 28-29 May 2026
📍 Naples, Italy
Preliminary Program: bit.ly/4w05Zbf
✉️ Information & participation: [email protected] - [email protected]
Roberto Contieri retweeted
To escalate or de-escalate treatment in BCG-naive HR NMIBC?
Our thoughts on the recent JCOG1019 trial by Kitamura et al @EUplatinum
Free access to full text 👇🏽
sciencedirect.com/science/ar…
@RobertoContieri @LAUrology_NL @UroDocAsh
Roberto Contieri retweeted
A multi-center study examines maintenance schedules for intermediate-risk #NMIBC. @RobertoContieri @IstTumori joins @UroDocAsh @UTMDAnderson to discuss the results which include two-year recurrence-free survival of 55% with no maintenance versus 78% with any maintenance. Classification and regression tree analysis identified optimal cutoff at more than six monthly instillations. #WatchNow on UroToday > bit.ly/3OEHP5m
Roberto Contieri retweeted
Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial by Roberto Contieri et al
Read the full article: buff.ly/AcADjoA
We thank the authors for trusting EUO to publish your work
@robertocontieri
@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@UroDocAsh
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect
Roberto Contieri retweeted
The International Bladder Cancer Group Travel Award to support outstanding fellows and early-career academic faculty committed to advancing the field of bladder cancer is now offered annually to provide emerging leaders the opportunity to participate in the IBCG Annual Retreat.
Details at link: ibcg.info/ibcg-2025-travel-a…
#BladderCancer #IBCG26
Roberto Contieri retweeted
Pleased to share that the 2026 @NCCN Bladder Cancer Guidelines now incorporate the @IBCG_BladderCa risk stratification framework for intermediate-risk NMIBC.
A milestone reflecting more than a decade of collaborative work by colleagues worldwide
einpresswire.com/article/901…
@UrogerliMD @drtanws @shilpaonc @pjhensley11 @mouwlab @AndreaNecchi @LAUrology_NL @AmirHorowitz @karima_oualla @PGrivasMDPhD @paolo_gontero @pcvblack @MaxKates @SpiessPhilippe @RobertoContieri @KKBree @LauraBukavinaMD @MRoupret @joanfundi @UroToday @BladderCancerUS @WorldBladderCan
Roberto Contieri retweeted
We validated BCG failure classifications
~5-year progression ≈30% in both BCG-exposed and BCG-unresponsive groups—but salvage RC is used more often in BCG-unresponsive pts
doi.org/10.1111/bju.70231 @Pietro9609 @UroMoschini @BenjaminPradere @RobertoContieri @SBoorjian @BJUIjournal
